<?xml version="1.0" encoding="UTF-8"?>
<ref id="B119-biomedicines-08-00060">
 <label>119.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Silk</surname>
    <given-names>A.W.</given-names>
   </name>
   <name>
    <surname>Kaufman</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Gabrail</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Mehnert</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Bryan</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Norrell</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Medina</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Bommareddy</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Shafren</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Grose</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial</article-title>
  <source>Cancer Res.</source>
  <year>2017</year>
  <volume>77</volume>
  <fpage>CT026</fpage>
 </element-citation>
</ref>
